BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 17580278)

  • 21. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
    Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
    Pathol Biol (Paris); 2000 Nov; 48(9):825-31. PubMed ID: 11141918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma.
    Choi JW; Lee JH; Park HS; Kim YS
    J Clin Pathol; 2011 Oct; 64(10):893-7. PubMed ID: 21725041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
    J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
    Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells.
    Alvarez-Millán JJ; Bocos C; Ferrín V; Lucas AR; Ruibal A; Schneider J
    Oncology; 2002; 62(3):286-90. PubMed ID: 12065877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic importance of the uPa/PAI-1 complex in breast cancer.
    Sten-Linder M; Seddighzadeh M; Engel G; Rutqvist LE; Linder S; Skoog L; Wima B
    Anticancer Res; 2001; 21(4B):2861-5. PubMed ID: 11712777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
    Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
    Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
    Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
    Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
    Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
    Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
    Gandolfo GM; Conti L; Vercillo M
    Anticancer Res; 1996; 16(4B):2155-9. PubMed ID: 8694536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
    Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
    Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
    Eroglu A; Ulu A; Cam R; Akar N
    J BUON; 2006; 11(4):481-4. PubMed ID: 17309181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
    Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
    BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
    De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
    Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
    Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer.
    Spyratos F; Bouchet C; Tozlu S; Labroquere M; Vignaud S; Becette V; Lidereau R; Bieche I
    Anticancer Res; 2002; 22(5):2997-3003. PubMed ID: 12530032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancer.
    Su CK; Yeh KT; Yeh CB; Wang PH; Ho ES; Chou MC; Liu KC; Yang SF; Yi YC
    J Surg Oncol; 2011 Dec; 104(7):755-9. PubMed ID: 21761413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens.
    Thomssen C; Harbeck N; Dittmer J; Abraha-Spaeth SR; Papendick N; Paradiso A; Lisboa B; Jaenicke F; Schmitt M; Vetter M
    J Natl Cancer Inst; 2009 Jul; 101(14):1028-9. PubMed ID: 19535782
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.